Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
24 July 2020Website:
http://www.nurixtx.comNext earnings report:
14 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 31 Oct 2024 20:37:00 GMTDividend
Analysts recommendations
Institutional Ownership
NRIX Latest News
Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical data from NX-5948 BTK degrader program
NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom's patients in the ongoing Phase 1a/1b clinical trial
SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of Anil Kapur to its board of directors, effective October 15, 2024. Mr. Kapur has over 25 years of executive experience in pharmaceutical and biotech companies across both U.S. and international markets.
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.67 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.68 per share a year ago.
Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA
Nurix Therapeutics, specializing in targeted protein degradation, shows promise with its clinical-stage candidates NX-1607, NX-5948, and NX-2127 for cancer and autoimmune diseases. Strong partnerships with Sanofi, Gilead, and Pfizer bolster Nurix's funding and technological capabilities, enhancing its potential for successful drug development and commercialization. Despite operating at a loss, Nurix's solid cash position and positive clinical trial results make it a compelling buy opportunity, though risks remain.
SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in September:
Does Nurix Therapeutics, Inc. (NRIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.45 per share a year ago.
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 1(current)
- 2
What type of business is Nurix Therapeutics?
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
What sector is Nurix Therapeutics in?
Nurix Therapeutics is in the Healthcare sector
What industry is Nurix Therapeutics in?
Nurix Therapeutics is in the Biotechnology industry
What country is Nurix Therapeutics from?
Nurix Therapeutics is headquartered in United States
When did Nurix Therapeutics go public?
Nurix Therapeutics initial public offering (IPO) was on 24 July 2020
What is Nurix Therapeutics website?
https://www.nurixtx.com
Is Nurix Therapeutics in the S&P 500?
No, Nurix Therapeutics is not included in the S&P 500 index
Is Nurix Therapeutics in the NASDAQ 100?
No, Nurix Therapeutics is not included in the NASDAQ 100 index
Is Nurix Therapeutics in the Dow Jones?
No, Nurix Therapeutics is not included in the Dow Jones index
When was Nurix Therapeutics the previous earnings report?
No data
When does Nurix Therapeutics earnings report?
The next expected earnings date for Nurix Therapeutics is 14 February 2025